Newswise — On March 11th 2020 the World Health Organization declared Coronavirus disease (COVID-19) a pandemic. In a few weeks the infection spread across the globe causing hundreds of thousands of deaths worldwide. Italy was the first European country to be hard-hit by the infection and among the countries with a higher mortality rate.
During the lockdown, Antonio Giordano, M.D., Ph.D., Founder and Director of the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University in Philadelphia, in collaboration with the University of Siena, Italy, reasoned about the possible causes of the heavy burden of infection in Italy and teamed up with researchers from different fields to investigate the possible causes. In an Opinion article published today in Frontiers in Immunology, the authors describe the main features of COVID-19 clinical course; the possible underlying mechanisms that contribute to exacerbate patient outcome; and the various strategies that can be adopted to tackle the disease and its complications.
In particular, the authors, anticipating their preliminary findings, put the spotlight on the Human Leukocyte Antigen (HLA) gene system, which has a key role in shaping the antiviral – innate and acquired – immune response. The authors, including Pierpaolo Correale and Rita Emilena Saladino, of the Grand Metropolitan Hospital of Reggio Calabria, Giovanni Baglio, of the Ministry of Health,
Francesca Pentimalli, of the National Cancer Institute ‘Pascale,” and Patrizia Maiorano, of the University of Siena, suggest that a specific immunogenetic asset constituted by particular variants of HLA genes could underlie susceptibility to the SARS-CoV-2 coronavirus, or predict a worse disease outcome.
“The identification of such immunogenetic determinants would be crucial to inform priorities in future vaccination campaigns, to decide clinical management strategies, and to isolate genetically at risk individuals, including healthcare workers,” says Luciano Mutti, MD, Oncologist and Adjunct Professor at the Sbarro Institute.
The study also raises another interesting possibility regarding the spreading of the infection in Italy, in which the northern region of the country, where the disease had been detected first, was most heavily hit. Although a massive migration from the affected regions to the south was recorded before the national lockdown, the southern regions registered much lower infection rates. However, it has been postulated that the virus was circulating long before the lockdown. While some have proposed that milder climate conditions could help to prevent viral spreading, could a specific immunogenetic asset contribute to protect southern Italian citizens? Further large-scale case-control studies will hopefully shed light on this possible aspect.
About the Sbarro Health Research Organization
The Sbarro Health Research Organization (SHRO) is non-profit charity committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other chronic illnesses and to foster the training of young doctors in a spirit of professionalism and humanism. To learn more about the SHRO please visit www.shro.org